Advancements in Immunotherapies With John DiPersio, MD, PhD

News
Article

The latest episode of the ASTCT Talks episode features John DiPersio, MD, PhD, on emerging therapies in the treatment of acute myeloid leukemia.

This episode of ASTCT Talks features a recently recorded conversation with John DiPersio, MD, PhD, a Bone Marrow Transplant Specialist and Medical Oncologist at the Siteman Cancer Center at the Washington University School of Medicine, and a past president of ASTCT. We discuss emerging therapies to treat acute myeloid leukemia, advancements in immunotherapies, and much more.

Tune in.

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. Like what you hear? Subscribe to ASTCT Talks and never miss an episode.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content